ディアストリック機能障害と閉塞性心不全
1Charles A. Dana Research Institute, Boston, Massachusetts.
Circulation
|February 1, 1990
まとめ
ダイアストリック心不全は,心室の充填が損なわれ,しばしばシストリック機能が保たれている. 構造的変化とリラックス異常がこの状態に寄与し,心臓の健康に影響を及ぼします.
科学分野:
- 心臓病学 心臓病学
- 心不全に関する研究
背景:
- ダイアストリック心不全 (DHF) は,心室充填に対する抵抗性の増加によって定義されます.
- 重要な患者グループは,正常な縮機能でDHFを示しています.
- DHFは,収縮性心膜炎や線維症などの構造的な問題から生じる可能性があります.
研究 の 目的:
- 心不全における下痢機能不全の根底にあるメカニズムを探求する.
- DHFにおける構造的および生理学的要因の役割を調査する.
- 立方体機能不全が肺腫のような疾患に与える影響を理解する.
主な方法:
- ディアストリック心不全に関する既存の文献のレビュー.
- 心室の構造的および生理学的異常の分析.
- 心筋縮症の検査とそのダイアストリック機能への影響.
主要な成果:
- DHFは,心筋外部のまたは心筋内部の構造的異常に起因する可能性があります.
- 心筋リラクゼーションとイナクティベーションの障害は,DHFの主要な要因です.
- 先進的な心筋縮症は,構造的変化とリラックス障害を伴い,下静脈流入抵抗を増加させる.
結論:
- ダイアストリック機能不全は,正常なエジェクション分数であっても,心不全の重要な構成要素です.
- 構造的異常と心筋リラクゼーションの障害は,DHFの中心です.
- DHFのメカニズムを理解することは,心不全や肺腫のような関連する合併症の管理に不可欠です.
関連する概念動画
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...


